The VITAL Amyloidosis Study: A Randomized, Double-Blind, Placebo-Controlled, Global, Phase 3 Study of NEOD001 in Patients with AL Amyloidosis and Cardiac Dysfunction

BLOOD

AMER SOC HEMATOLOGY

1. Gilead
2. Pfizer
3. Novartis
4. Amgen
5. Prothena
6. Takeda
7. Celgene
8. Onyx/Amgen
9. Janssen
10. Karyopharm
11. Ionis
12. Prothena Therapeutics
13. Alnylam Pharmaceuticals